Astellas, GSK In Race For Anemia Drug With High-Altitude Feeling
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and GlaxoSmithKline are in a race to develop a new type of drug for treating anemia by causing the body to feel it is at a high altitude, a pill considered worth about $8 billion a year.